SG10201701933XA - Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers - Google Patents

Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Info

Publication number
SG10201701933XA
SG10201701933XA SG10201701933XA SG10201701933XA SG10201701933XA SG 10201701933X A SG10201701933X A SG 10201701933XA SG 10201701933X A SG10201701933X A SG 10201701933XA SG 10201701933X A SG10201701933X A SG 10201701933XA SG 10201701933X A SG10201701933X A SG 10201701933XA
Authority
SG
Singapore
Prior art keywords
receptor alpha
folate receptor
diagnostic
prognostic marker
expressing cancers
Prior art date
Application number
SG10201701933XA
Other languages
English (en)
Inventor
Daniel J O'shannessy
Luigi Grasso
Shanhong Wan
Qimin Chao
Elizabeth Brooke Somers
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of SG10201701933XA publication Critical patent/SG10201701933XA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201701933XA 2010-11-05 2011-11-04 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers SG10201701933XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41049710P 2010-11-05 2010-11-05
US201161508444P 2011-07-15 2011-07-15

Publications (1)

Publication Number Publication Date
SG10201701933XA true SG10201701933XA (en) 2017-05-30

Family

ID=45003076

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2013030424A SG189957A1 (en) 2010-11-05 2011-11-04 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
SG10201701933XA SG10201701933XA (en) 2010-11-05 2011-11-04 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
SG10201509145XA SG10201509145XA (en) 2010-11-05 2011-11-04 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013030424A SG189957A1 (en) 2010-11-05 2011-11-04 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201509145XA SG10201509145XA (en) 2010-11-05 2011-11-04 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Country Status (14)

Country Link
US (1) US20120207771A1 (fr)
EP (2) EP2635304B1 (fr)
JP (2) JP6224456B2 (fr)
KR (2) KR102057438B1 (fr)
CN (2) CN103687618A (fr)
AU (3) AU2011323124C1 (fr)
BR (1) BR112013011072B1 (fr)
CA (1) CA2816991C (fr)
ES (2) ES2780192T3 (fr)
IL (2) IL225871B (fr)
MX (2) MX343607B (fr)
RU (2) RU2630608C2 (fr)
SG (3) SG189957A1 (fr)
WO (1) WO2012061759A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006241099B2 (en) * 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
DK2538976T3 (en) 2010-02-24 2017-02-27 Immunogen Inc IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF
US20120189620A1 (en) * 2011-01-21 2012-07-26 Emory University Methods for treating non-functioning pituitary adenoma
WO2012119077A1 (fr) * 2011-03-02 2012-09-07 Morphotek Inc. Co-administration d'éribuline et de farletuzumab pour le traitement du cancer du sein
IL281714B2 (en) * 2011-04-01 2023-11-01 Immunogen Inc Methods for increasing the effectiveness of FOLR1 cancer therapy
TR201802838T4 (tr) * 2011-07-15 2018-03-21 Eisai R&D Man Co Ltd Anti-folat reseptör alfa antikorlar ve bunların kullanımı.
ES2766836T3 (es) 2012-05-15 2020-06-15 Eisai Inc Métodos para el tratamiento de cáncer gástrico
IL299620A (en) * 2012-08-31 2023-03-01 Immunogen Inc Tests and diagnostic kits for the detection of folate receptor 1
AU2014284212B2 (en) * 2013-06-20 2019-09-12 Eisai, Inc. Methods for treatment of ovarian cancer
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
CN106164093A (zh) * 2013-10-08 2016-11-23 伊缪诺金公司 抗folr1免疫偶联物给药方案
PL3221355T3 (pl) 2014-11-20 2021-03-08 F. Hoffmann-La Roche Ag Terapia skojarzona składająca się z dwuswoistych aktywujących limfocyty T cząsteczek wiążących antygen CD3 i receptor folianowy 1 (FolR1) oraz antagonistów wiązania osi PD-1
KR20170137848A (ko) 2015-04-17 2017-12-13 모르포테크, 인크. 폐암을 치료하는 방법
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
CN109789212A (zh) 2016-08-12 2019-05-21 L.E.A.F.控股集团公司 聚谷氨酸化抗叶酸剂及其用途
EP3544999A1 (fr) 2016-11-23 2019-10-02 Eisai R&D Management Co., Ltd. Anticorps anti-récepteurs alpha du folate et leurs utilisations
CN107446021B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽5及其应用
CN107353325B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽1及其应用
CN107446020B (zh) * 2017-07-28 2019-10-01 中国药科大学 叶酸受体α特异性结合肽2及其应用
KR102643780B1 (ko) * 2017-09-05 2024-03-05 이뮤노젠 아이엔씨 환자 샘플에서 엽산 수용체 1의 검출 방법
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019160734A1 (fr) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Lométrexol gamma polyglutamique et ses utilisations
CA3090753A1 (fr) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Pralatrexate gamma-polyglutamate et utilisations associees
CN115925952A (zh) * 2018-03-13 2023-04-07 东莞凡恩世生物医药有限公司 抗叶酸受体1抗体及其用途
CA3128973A1 (fr) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Compression et communication de donnees a l'aide d'un apprentissage automatique
JP2022530524A (ja) 2019-04-29 2022-06-29 イミュノジェン， インコーポレイテッド バイパラトピックＦＲ－α抗体及びイムノコンジュゲート
TW202306995A (zh) * 2021-06-04 2023-02-16 美商免疫遺傳股份有限公司 治療具有可溶性ＦＲ－α之患者之癌症
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
PT656946E (pt) 1992-08-21 2001-12-28 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2153387A1 (fr) 1993-01-07 1994-07-21 Hubert Koester Sequencage de l'adn par spectrometrie de masse
AU687801B2 (en) 1993-03-19 1998-03-05 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
RU2233878C2 (ru) 1997-01-21 2004-08-10 Дзе Дженерал Хоспитал Корпорейшн Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6933108B2 (en) * 1999-12-09 2005-08-23 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
EP1332367A2 (fr) * 2000-11-01 2003-08-06 Mount Sinai Hospital Detection du cancer de l'ovaire
US20100120078A1 (en) * 2001-08-16 2010-05-13 Tony Baker Urine Stabilization System
WO2003042240A2 (fr) * 2001-11-13 2003-05-22 Shire Biochem Inc. Polypeptides de pseudomonas aeruginosa
AU2003253589A1 (en) * 2002-03-26 2003-11-10 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
WO2004082463A2 (fr) * 2003-03-17 2004-09-30 Medical College Of Ohio Modulation de gene par recepteur de folate pour diagnostic et therapie de cancer
CA2526647A1 (fr) 2003-05-23 2004-12-29 Morphotek, Inc. Anticorps monoclonaux se liant specifiquement a un antigene tumoral
EP1682675A2 (fr) * 2003-10-28 2006-07-26 Bayer HealthCare AG Procedes et compositions de prediction de reponse de la neoplasie maligne a un traitement
EP3101034A1 (fr) 2004-02-12 2016-12-07 Morphotek, Inc. Anticorps monoclonaux se liant spécifiquement au récepteur alpha du folate
JP2008537778A (ja) * 2005-03-30 2008-09-25 パーデュー・リサーチ・ファウンデーション 細胞の葉酸ビタミン受容体の定量化による癌予後診断法
AU2006241099B2 (en) * 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
EP1996940B1 (fr) * 2006-02-09 2011-12-21 University of South Florida Détection d'un cancer par dépistage de taux élevés de bcl-2
US8486412B2 (en) * 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
EP1900752A1 (fr) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Anticorps monoclonaux humains et ses fragments liant spécifiquement le récepteur alpha de l'acide folique pour l'immunothérapie du cancer de l'ovaire
US7754698B2 (en) 2007-01-09 2010-07-13 Isis Pharmaceuticals, Inc. Modulation of FR-alpha expression
US20100216718A1 (en) * 2007-10-19 2010-08-26 Cell Signaling Technology, Inc. Cancer Classification and Methods of Use
WO2009132081A2 (fr) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Ciblage à base d’anticorps monoclonaux des récepteurs de folate
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
EP2606353A4 (fr) * 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings Biomarqueurs circulants pour une maladie

Also Published As

Publication number Publication date
MX343607B (es) 2016-11-11
US20120207771A1 (en) 2012-08-16
JP6224456B2 (ja) 2017-11-01
CN103687618A (zh) 2014-03-26
JP6554152B2 (ja) 2019-07-31
IL260590B (en) 2020-01-30
EP3130605A1 (fr) 2017-02-15
ES2780192T3 (es) 2020-08-24
AU2011323124C1 (en) 2016-09-22
AU2011323124B2 (en) 2016-02-25
KR102057438B1 (ko) 2019-12-20
SG10201509145XA (en) 2015-12-30
IL225871B (en) 2018-08-30
RU2630608C2 (ru) 2017-09-11
BR112013011072A2 (pt) 2017-06-20
EP2635304B1 (fr) 2017-03-08
AU2011323124A1 (en) 2013-05-09
KR101931936B1 (ko) 2018-12-26
CN108562744A (zh) 2018-09-21
SG189957A1 (en) 2013-06-28
RU2013125772A (ru) 2014-12-10
EP3130605B1 (fr) 2020-01-08
WO2012061759A2 (fr) 2012-05-10
RU2017129266A (ru) 2019-02-04
AU2016203408A1 (en) 2016-06-16
ES2627061T3 (es) 2017-07-26
CA2816991A1 (fr) 2012-05-10
CA2816991C (fr) 2020-06-09
EP2635304A2 (fr) 2013-09-11
IL225871A0 (en) 2013-06-27
KR20140024838A (ko) 2014-03-03
JP2018036270A (ja) 2018-03-08
BR112013011072B1 (pt) 2021-02-02
KR20180137587A (ko) 2018-12-27
RU2764592C2 (ru) 2022-01-18
WO2012061759A3 (fr) 2012-07-26
AU2018201760A1 (en) 2018-04-05
AU2018201760B2 (en) 2019-07-25
MX2013005067A (es) 2013-07-02
RU2017129266A3 (fr) 2021-01-25
MX368394B (es) 2019-10-01
JP2013544354A (ja) 2013-12-12

Similar Documents

Publication Publication Date Title
IL260590B (en) Receptor alpha emitting as a diagnostic and prognostic marker for cancer expressing receptor alpha emitting
HK1135940A1 (en) Self-powered coordinate probe
EP2585833A4 (fr) Procédés de détection de cancer
EP2630917A4 (fr) Appareil de mesure de sein
EP2592383A4 (fr) Appareil de mise à disposition d'informations
EP2569446A4 (fr) Marqueurs diagnostiques pour maladie neuropsychiatrique
GB201414085D0 (en) Breast cancer diagnosis and indication marker
EP2636040A4 (fr) Opérations de réécriture
EP2748608A4 (fr) Tests du cancer du poumon
EP2634544A4 (fr) Goulotte collective pour balance combinatoire
GB201012590D0 (en) Methods for diagnosing cancer
EP2524702A4 (fr) Diagnostic pour le cancer
EP2495561A4 (fr) Marqueur permettant de déterminer la sensibilité à un agent anticancéreux
ZA201200888B (en) New tumor marker
EP2531616A4 (fr) Dosage de diagnostic et de pronostic pour le cancer du sein
GB201414102D0 (en) Colorectal cancer diagnosis and indication marker
GB2477687B (en) X-ray marker
GB0908071D0 (en) Marker
EP2735571A4 (fr) Anticorps pour un marqueur du cancer colorectal
PT2386459E (pt) Sistema de localização de comboios
GB0905964D0 (en) Marker
GB2484553B (en) A tunnelling device
GB201016212D0 (en) Marker device
GB201001946D0 (en) Cancer prognostic assay
WO2012040583A9 (fr) Ancca en tant que biomarqueur de diagnostic et cible thérapeutique pour les cancers du sein